Drug Trial Radar · NCT05287308
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
Last checked: Nov 20, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 2022
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CSPC Ouyi Pharmaceutical Co., Ltd.
- First posted
- Mar 18, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.
Conditions
- Breast Cancer
Interventions
doxorubicinDrug
doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
epirubicinDrug
epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
pirarubicinDrug
pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
cyclophosphamideDrug
cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
albumin-bound paclitaxelDrug
albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
paclitaxelDrug
paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
docetaxelDrug
docetaxel 80\~100mg/m2, i.v., d1, q3w.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year invasive disease-free survival (IDFS) rateTime frame: up to 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, ChineseAMS
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.